Genetic diversity of the host and severe respiratory syncytial virus-induced lower respiratory tract infection

Pediatric Infectious Disease Journal

Volumn 28, Issue 2, 2009, Pages 135-140

  Amanatidou, Virginia ^a   Apostolakis, Stavros ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Bronchiolitis; Genetic markers; Genetic polymorphisms; Respiratory syncytial virus

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FRACTALKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 8; RANTES; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1;

ALLELE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; LOWER RESPIRATORY TRACT INFECTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS INFECTION;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 61949464358     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818c8d17     Document Type: Review

References (77)

1. Simoes EA. Respiratory syncytial virus infection. Lancet.1999;354: 847-852.
2. Hashem M, Hall CB. Respiratory syncytial virus in healthy adults: the cost of a cold. JClin Virol.2003;27:14-21.
3. Falsey AR, Hennessey RN, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N EnglJMed.2005;352:1749-1759.
4. Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med.2002;8:214-217.
5. Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. JInf Dis.1991;163:693-698.
6. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA.1999;282:1440-1446.
7. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol.2004;17:165-181.
8. Staat MA. Respiratory syncytial virus infections in children. Semin Respir Infect.2002;17:15-20.
9. CDC Brief Report RSV Activity-U.S. 2006-2007.
10. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J.2003;22:13-18.
11. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev.2000;13:371.
12. Graham BS, Johnson TR, Peebles R. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology.2000;48:237- 247.
13. Harrison AM, Bonville CA, Rosenberg HF, et al. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am JRespir Crit Care Med.1999;159:1918 -1924.
14. Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol.2004;17:370-380.
15. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J.2003;22:S6-S10.
16. Tripp RA, Oshansky C, Alvarez R. Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc.2005;2:147-149.
17. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. JInfect Dis.2004;189:1419-1430.
18. Sheeran P, Jafri H, Carubelli C, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J.1999;18:115-122.
19. Tripp RA, Moore D, Barskey A, et al. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. JInfect Dis.2002;185:1388 -1394.
20. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med.2002; 96(suppl B):1-7.
21. Moler FW, Khan AS, Meliones JN, et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med.1992;20:1406-1413.
22. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplantpatients. Transplantation.2003;76: 142-146.
23. Carpenter TC, Stenmark KR. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatr Infect Dis J.2004;23:S33-S40.
24. Carbonell-Estrany X, Figueras-Aloy J, Law BJ; for the Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J.2004;23:S193-S201.
25. Power UF. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. JClin Virol.2008;41:38-44.
26. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res.2007;39:225-239.
27. Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use ofRSV-IGIV. Pediatrics.1998;102:1211- 1216.
28. DeVincenzo JP. Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J.2005; 24:S177-S183.
29. Welliger RC, Garofalo RP, Ogra PL. Beta chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J.2002;21:457-461.
30. Amanatidou V, Sourvinos G, Apostolakis S, et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J.2008;27:38-42.
31. Puthothu B, Krueger M, Forster J, et al. Interleukin (IL)-18 polymorphism 133C/Gisassociatedwithsevere respiratorysyncytialvirusinfection. Pediatr Infect Dis J.2007;26:1094-1098.
32. Awomoyi AA, Rallabhandi P, Pollin TI, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol.2007;179:3171-3177.
33. Krueger M, Puthothu B, Heinze J, et al. Genetic polymorphisms of adhesion molecules in children with severe RSV-associated diseases. Int J Immunogenet.2006;33:233-235.
34. Puthothu B, Krueger M, Heinze J, et al. Impact of IL8 and IL8-receptor alpha polymorphisms on the genetics of bronchial asthma and severe RSV infections. Clin Mol Allergy.2006;4:2.
35. Amanatidou V, Sourvinos G, Apostolakis S, et al. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J.2006;25:410-414.
36. Hoebee B, Rietveld E, Bont L, et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. JInfect Dis.2003;187:2-11.
37. Heinzmann A, Ahlert I, Kurz T, et al. Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis. JAllergy Clin Immunol.2004;114:671-676.
38. Gibbons GH, Liew CC, Goodarzi MO, et al. Genetic markers: progress and potential for cardiovascular disease. Circulation.2004;109:IV47-IV58.
39. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev.2004;5:S119-S126.
40. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. NEngl JMed.1998;338:436-445.
41. Apostolakis S, Papadakis GE, Krambovitis E, et al. Chemokines in vascular pathology. Int JMol Med.2006;17:691-701.
42. Johnson TR, Mertz SE, Gitiban N, et al. Role for innate IFNs in determining respiratorysyncytial virus immunopathology. JImmunol. 2005;174:7234-7241.
43. 3. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature.1997;385:640-644.
44. 4. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell.1997;91:521-530.
45. Tripp RA, Dakhama A, Jones PL, et al. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. JVirol.2003;77:6580-6584.
46. Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol.2001;2:732-738.
47. Culley FJ, Pennycook AM, Tregomng JS, et al. Role of CCL5 (RANTES) in viral lung disease. JVirol.2006;80:8151-8157.
48. Hull J, Rowlands K, Lockhart E, et al. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. JInfect Dis.2003;188:904-907.
49. Bonville CA, Rosenberg HF, Domachowske JB. Macrophage inflammatory protein-1alpha and RANTES are present in nasal secretions during ongoing upper respiratory tract infection. Pediatr Allergy Immunol.1999;10:39-44.
50. Kunkel SL, Standiford T, Kasahara K, et al. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res.1991;17:17-23.
51. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax.2000;55:1023-1027.
52. Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet.2001;69:413-419.
53. 3. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun.2002;297:700-713.
54. 4. Apostolakis S, Vogiatzi K, Krambovitis E, et al. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem.2008;6:150-158.
55. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes.2006;33:235-252.
56. Gentile DA, Doyle WJ, Zeevi A, et al. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol.2003;64:338-344.
57. Wilson J, Rowlands K, Rockett K, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. JInfect Dis.2005;191:1705-1709.
58. Hoebee B, Bont L, Rietveld E, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. JInfect Dis.2004;189:239-247.
59. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member ofthe IL-1 family. JAllergy Clin Immunol.1999;103:11-24.
60. Wild JS, Sigounas A, Sur N, et al. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model ofallergic asthma. JImmunol.2000;164:2701- 2710.
61. Moore KW, deWaal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol.2001;19:683-765.
62. Gentile DA, Doyle WJ, Zeevi A, et al. Cytokine gene polymorphisms moderate responses to respiratory syncytial virus in adults. Hum Immunol.2003;64:93-98.
63. 3. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell.2008;132: 259-272.
64. 4. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review ofthe literature. Respir Res.2003;4:14.
65. 5. Puthothu B, Krueger M, Forster J, et al. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis.2006; 193:438 -441.
66. Vogel SN, Fitzgerald KA, Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates. TLR-specific patterns of gene expression. Mol Interv.2003;3:466-477.
67. Haeberle HA, Takizawa R, Casola A, et al. Respiratory syncytial virus-induced activation of nuclear factor-kappa B in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis.2002;186:1199-1206.
68. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol.2000;1:398-401.
69. Haynes LM, Moore DD, Kurt-Jones EA, et al. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol.2001; 75:10730-10737.
70. Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis.2004;189:2057-2063.
71. Puthothu B, Forster J, Heinzmann A, et al. TLR-l and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers.2006;22: 303-308.
72. Paulus SC, Hirschfeld AF, Victor RE, et al. Common human Toll-like receptor 4 polymorphisms-ole in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol.2007;123: 252-257.
73. 3. Inoue Y, Shimojo N, Suzuki Y, et al. CD14-550 C/T, which is related to the serum level of soluble CD14, is associated with the development of respiratory syncytial virus bronchiolitis in the Japanese population J Infect Dis.2007;195:1618-1624.
74. 4. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol.2005;5:58-68.
75. 5. Puthothu B, Forster J, Heinze J, et al. Surfactant protein B polymorphisms are associated with severe respiratory syncytial virus infection, but not with asthma. BMC Pulm Med.2007;7:6.
76. 6. Lahti M, Lofgren J, Marttila R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res.2002;51:696-699.
77. Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis.2007;196:826-834.